1. Home
  2. VERU vs NA Comparison

VERU vs NA Comparison

Compare VERU & NA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Veru Inc.

VERU

Veru Inc.

N/A

Current Price

$2.63

Market Cap

48.2M

Sector

Health Care

ML Signal

N/A

NA

Nano Labs Ltd

N/A

Current Price

$1.88

Market Cap

43.4M

Sector

Technology

ML Signal

N/A

Company Overview

Basic Information
Metric
VERU
NA
Founded
1971
2019
Country
United States
China
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Semiconductors
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
48.2M
43.4M
IPO Year
1996
2021

Fundamental Metrics

Financial Performance
Metric
VERU
NA
Price
$2.63
$1.88
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
$22.50
N/A
AVG Volume (30 Days)
278.7K
13.6K
Earning Date
05-12-2026
03-30-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$16,296,958.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.05
$1.58
52 Week High
$7.33
$6.30

Technical Indicators

Market Signals
Indicator
VERU
NA
Relative Strength Index (RSI) 54.95 51.88
Support Level $2.12 $1.64
Resistance Level $2.67 $1.96
Average True Range (ATR) 0.14 0.09
MACD 0.06 0.01
Stochastic Oscillator 65.75 79.48

Price Performance

Historical Comparison
VERU
NA

About VERU Veru Inc.

Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.

About NA Nano Labs Ltd

Nano Labs Ltd is a Web 3.0 infrastructure and product solution provider, as well as a crypto treasury company. It is focused on the development of HTC chips and HPC chips. In addition, the company has established BNB value investment and adopted BNB (a crypto token) as the primary reserve asset. Furthermore, it has launched the iPollo Claw, a dedicated hardware solution for the OpenClaw AI Agent Ecosystem. Nano Labs derives revenue mainly from its HTC and HPC offerings, which comprise Darkbird series HPC chips that feature high performance and high energy consumption efficiency, and Cuckoo series chips, used in GPUs. Geographically, the company generates maximum revenue from the People's Republic of China (PRC), and the rest from Singapore, Hong Kong, the United States, and other markets.

Share on Social Networks: